DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04175665

Completed

Real-world Health Outcomes in Canadian Patients Using Semaglutide

Semaglutide in Patients With Type 2 Diabetes: Real-world Analysis in the Canadian LMC Diabetes Registry: The SPARE Study

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1,133

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04175665
Org study IDSPARE

Timeline

Milestones

Study first posted2019-11-25actual
Study start2020-01-06actual
Primary completion2020-02-09actual
Study completion2020-02-09actual
Last update posted2020-02-21actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

The study population will be patients with type 2 diabetes who initiate semaglutide between February 1, 2018 and February 1, 2019 as part of usual clinical care, and who are active patients at LMC Diabetes \& Endocrinology.

Inclusion criteria

•First prescription for semaglutide between Feb 1 2018 and Feb 1 2019
•Age ≥ 18 years at medication index date
•Clinical diagnosis of type 2 diabetes for greater than six months
•≥ one HbA1c measurement at baseline and at follow-up
•≥ one follow-up visit post index date
•Informed consent for medical data to be used for research purposes

Exclusion criteria

•Clinical diagnosis of type 1 diabetes
•Recent eGFR <40 ml/min/1.73m2
•Documented history of bariatric surgery

Endpoints (37)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
15
Weight & body composition
12
Cardiometabolic biomarkers
5
Safety / tolerability / PK
3
MASH / liver
1
Renal / kidney
1

Weight & body composition

12 endpoints
Secondary/protocol endpoint

Change in body weight

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in body mass index (BMI)

Time frame:3 to 6 months

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Proportion of patients who achieve weight loss ≥5%

Time frame:3 to 6 months

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of patients who achieve weight loss ≥10%

Time frame:3 to 6 months

≥10% weight-loss responders

threshold achievement, improvement

Other/protocol endpoint

Body weight change in low dose therapy and high dose therapy subgroups

Time frame:3 to 6 months

change from baseline, improvement

Other/protocol endpoint

Body weight change in patients who discontinue a DPP-4i at baseline versus simple addition of semaglutide

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Body weight change in patients who discontinue any diabetes therapy at baseline versus simple addition of semaglutide

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Weight change in insulin users and non-insulin users

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Weight change in patients who have a 13-week follow-up versus a 26-week follow-up

Time frame:3 to 6 months

change from baseline, improvement

Other/protocol endpoint

Weight change in patients prescribed semaglutide as second line therapy (excluding insulin use)

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Weight change in patients prescribed semaglutide as third line therapy (excluding insulin use)

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other/protocol endpoint

Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use)

Time frame:3 to 6 months

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

15 endpoints
Primary/protocol endpoint

Change in HbA1c

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of patients who achieve HbA1c ≤7.0%

Time frame:3 to 6 months

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of patients who achieve HbA1c ≤8.0%

Time frame:3 to 6 months

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of patients who achieve HbA1c reduction ≥0.5%

Time frame:3 to 6 months

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Proportion of patients who achieve HbA1c reduction ≥1.0%

Time frame:3 to 6 months

HbA1c, % change

threshold achievement, improvement

LOINC 4548-4

Other/protocol endpoint

Time to addition of another diabetes therapy

Time frame:3 to 6 months

time to event, event

Other/protocol endpoint/low confidence

Insulin dose at baseline and follow-up

Time frame:3 to 6 months

descriptive

Other/protocol endpoint

HbA1c change in low dose therapy and high dose therapy subgroups

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients who discontinue a dipeptidyl peptidase-4 inhibitor (DPP-4i) at baseline versus simple addition of semaglutide

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients who discontinue any diabetes therapy at baseline versus simple addition of semaglutide

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in insulin users and non-insulin users

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients who have a 13-week follow-up versus a 26-week follow-up

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients prescribed semaglutide as second line therapy (excluding insulin use)

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients prescribed semaglutide as third line therapy (excluding insulin use)

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Other/protocol endpoint

HbA1c change in patients prescribed semaglutide as fourth line therapy (excluding insulin use)

Time frame:3 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

1 endpoint
Secondary/protocol endpoint

Change in alanine amino transaminase (ALT)

Time frame:3 to 6 months

ALT, change

change from baseline, improvement

LOINC 1742-6

Renal / kidney

1 endpoint
Secondary/protocol endpoint

Change in estimated glomerular filtration rate (eGFR)

Time frame:3 to 6 months

eGFR, change

change from baseline, improvement

LOINC 98979-8

Cardiometabolic biomarkers

5 endpoints
Secondary/protocol endpoint

Change in systolic blood pressure (SBP)

Time frame:3 to 6 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in diastolic blood pressure (DBP)

Time frame:3 to 6 months

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in triglycerides

Time frame:3 to 6 months

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in LDL cholesterol

Time frame:3 to 6 months

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in non-HDL cholesterol

Time frame:3 to 6 months

Non-HDL cholesterol, change

change from baseline, improvement

Safety / tolerability / PK

3 endpoints
Secondary/protocol endpoint

Proportion of patients who report ≥ 1 weekly incidence of any hypoglycemia

Time frame:3 to 6 months

Documented hypoglycemia

threshold achievement, event

Secondary/protocol endpoint

Proportion of patients who report ≥ 1 yearly incidence of severe hypoglycemia

Time frame:3 to 6 months

Severe hypoglycemia

threshold achievement, event

Other/protocol endpoint

Time to discontinuation of GLP-1 RA therapy

Time frame:3 to 6 months

Discontinuation due to AE

time to event, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.